Basket

  Untick selected:   0
  1. Advanced NSCLC treated with gefitinib or erlotinib for five years or longer - updated data from the retrospective Slovakian study  / Peter Beržinec, Peter Kasan, Juraj Mazal .  Abstract IASLC 2019 World Conference on Lung Cancer   [Dokument nie je vo fonde knižnice]
    article

    article


  This site uses cookies to make them easier to browse. Learn more about how we use cookies.